Sera Prognostics is a women’s health diagnostics company dedicated to improving the lives of women and babies. Sera is the first to launch a simple blood test (PreTRM®) that biologically identifies, and reports, to a physician the individualized risk of spontaneous premature delivery in a pregnancy. Early identification of higher risk, and appropriate evidence-based treatment, can help to prolong gestational age at birth, improve newborn health and reduce NICU days and associated costs.
Sera’s PreTRM® Test provides employers value through an innovative solution to reduce high dollar claims associated with maternal and neonatal care. PreTRM® can be featured as a key component for building impactful Diversity and Inclusion programs, as African and Native American women have the highest preterm birth rates in the U.S.
PreTRM® provides employers with added value to attract and retain new talent, reduce health care costs, while keeping their workforce engaged and productive at work. Absenteeism, presenteeism, mental health conditions, and resignations caused by premature labor can be mitigated, further contributing to savings.
Customized, employer specific clinical and economic impact estimates are available on request.